The presence of a KRAS mutation, which can identify those individuals best treated with epidermal growth factor receptor (EGFR) inhibitors, provides welcome clarity to clinicians. But from a ...

Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC ...

[2] Good evidence exists for the use of anti-EGF receptor (EGFR) monoclonal antibody treatment as part of first-line combination chemotherapy including infusional 5-fluorouracil and for third-line ...

The results showed objective responses in 32 of 94 patients treated with the KRAS inhibitor adagrasib (Krazati) and the EGFR inhibitor cetuximab (Erbitux). An additional 48 patients had stable ...

In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.

Some colorectal and pancreatic cancers may be resistant to KRAS G12C inhibitors due to co-occurring genetic alterations, according to a study published in the AACR journal Clinical Cancer Research.

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for adults with KRAS G12C-mutated metastatic colorectal cancer (CRC ...

EGFR_ECD, extracellular domain mutations of EGFR ... (C) Incidence of co-occurring KRAS and PIK3CA mutations.

The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.

An EGFR gene mutation is one of the biomarkers a doctor often tests for after confirming a diagnosis of non-small cell lung cancer (NSCLC). Biomarkers can help guide treatment. EGFR mutations ...

The KRAS and epidermal growth factor receptor (EGFR) mutations are among the most common gene mutations doctors test for in NSCLC. A doctor or pathologist can use various techniques to test for ...

Clearly, nonreceptor changes may also account for resistance to mAb therapy targeting the EGFR, and may include extracellular sequestration of drug or immune modulation affecting antibody ...